FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 31 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction... November 17, 2023 Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 People with Cancer Say Access to Their Clinical Notes Is Valuable November 18, 2020 Load more HOT NEWS Prize winning early detection research Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... New Research Looks for More Effective Breast Cancer Treatments for Black... New insights on self-sampling for cervical cancer screening
